{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Oral erlotinab at 150mg constant dose, 3 pts will be treated with temsirolimus IV with escalating doses, starting at 50mg. Doses will increase or decrease based on toxicity observed.\n\n3 pts will be treated at each dose level - 3 dose levels were observed: 50mg, 25mg, and 15mg","groups":[{"description":"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at (dose escalation or dose de-escalation). Every 28 days until disease progression or unacceptable toxicity.\n\nDose levels: cohort 1 - 50mg - 3pts cohort 2 - 25mg -6pt cohort 3 - 15mg - 12pts","id":"OG000","title":"Phase I - Dose Escalation"}],"paramType":"NUMBER","populationDescription":"Per protocol -","reportingStatus":"POSTED","timeFrame":"based on first 4 weeks of treatment - cycle 1","title":"Maximum Tolerated Dose (Phase I)","type":"PRIMARY","unitOfMeasure":"mg"}